The Approval Process in Action

Life Sciences Tools & DiagnosticsMedical DevicesRegenerative MedicineBiotechnology / Pharmaceuticals

Source: The Life Sciences Report and Visual Capitalist (5/1/13)

What catalysts in the drug development process move biotech company stocks? The savvy investor must know what steps in the U.S. Food and Drug Administration's approval process can propel a stock up or down. From drug discovery to the much-anticipated PDUFA date, The Life Sciences Report and the Visual Capitalist have collaborated on an infographic that describes both the process and related catalysts.

An AI-Powered Doctor & Patient Platform: Why This North American Provider is Gaining Market Momentum
Source: Stewart Thomson (03/17/2026)

Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA).

Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch
Source: Andrew Fein (03/16/2026)

H.C. Wainwright reiterated its rating and price target on Savara Inc. (SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market.

BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note.

A New Infection Control Platform Launched
Source: John Newell (03/11/2026)

John Newell of John Newell & Associates shares his thoughts on BioLargo Inc. (BLGO:OTCQX) to explain why he thinks the stock is a Speculative Buy.

Analyst Maintains Spec Buy on Biotech After Interim SAT-3247 DMD Data
Source: Dr. Douglas Loe (03/11/2026)

Leede Financial maintained its rating on Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ), with a US$16.00 price target following updated interim Phase II SAT-3247 data from the TRAILHEAD trial in Duchenne muscular dystrophy.